Bonaventure Pascal, Nepomuceno Diane, Kwok Annette, Chai Wenying, Langlois Xavier, Hen Rene, Stark Kimberly, Carruthers Nicholas, Lovenberg Timothy W
Johnson & Johnson Pharmaceutical Research and Development L.L.C, 3210 Merryfield Row, San Diego, CA 92121, USA.
J Pharmacol Exp Ther. 2002 Jul;302(1):240-8. doi: 10.1124/jpet.302.1.240.
The characterization and anatomical distribution of 5-hydroxytryptamine (5-HT)(7) receptor binding sites in brain tissue has been hampered by the lack of a specific radioligand. In the present autoradiographic study, we took advantage of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice to revisit the pharmacological characterization and anatomical localization of 5-HT(7) binding sites in mouse brain using [(3)H]5-carboxamidotryptamine (5-CT) and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline (8-OH-DPAT). The distribution pattern of [(3)H]5-CT binding sites (2 nM) in the brain of mice lacking the 5-HT(1A/1B) receptor was scarce and confined to the septum, globus pallidus, thalamus, hypothalamus, amygdala, cortex, and substantia nigra. The low densities of [(3)H]5-CT binding sites detected in septum, thalamus, hypothalamus, amygdala, and cortex were displaced by 10 microM of the selective 5-HT(7) receptor antagonist (R)-3-(2-(2-(4-methylpiperidin-1-yl) ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970). The SB-269970-insensitive [(3)H]5-CT binding sites detected in globus pallidus and substantia nigra of 5-HT(1A/1B) knockout mice were displaced by N-[3-(2-dimethylamino)ethoxy-4-methoxy-phenyl]-2'-methyl-4'- (5-methyl-1,2,4-oxadiazol-3-yl)-(1,1'-biphenyl)-4-carboxamide hydrochloride (SB-216641) (1 microM), demonstrating the 5-HT(1D) nature of these binding sites. In contrast to the low densities of [(3)H]5-CT binding sites, high-to-moderate densities of [(3)H]8-OH-DPAT binding sites (10 nM) were found throughout the brain of 5-HT(1A) and 5-HT(1A/1B) knockout mice (olfactory system, septum, thalamus, hypothalamus, amygdala, CA3 field of the hippocampus, cortical mantle, and central gray). These [(3)H]8-OH-DPAT binding sites were displaced by 10 microM SB-269970, risperidone, and methiothepin but not by pindolol, N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide (WAY- 100135), or citalopram. We conclude that despite its high affinity for the 5-HT(7) receptor in tissue homogenates, [(3)H]5-CT is not a good tracer for measuring 5-HT(7) receptor binding sites autoradiographically. Also, the lower affinity ligand [(3)H]8-OH-DPAT is a much better tracer for autoradiographic studies at the 5-HT(7) receptor binding sites.
缺乏特异性放射性配体阻碍了对脑组织中5-羟色胺(5-HT)(7)受体结合位点的特性及解剖分布的研究。在本放射自显影研究中,我们利用5-HT(1A)基因敲除小鼠和5-HT(1A/1B)双基因敲除小鼠,使用[(3)H]5-羧基酰胺色胺(5-CT)和[(3)H]8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)重新研究小鼠脑中5-HT(7)结合位点的药理学特性和解剖定位。在缺乏5-HT(1A/1B)受体的小鼠脑中,[(3)H]5-CT结合位点(2 nM)的分布模式稀少,局限于隔区、苍白球、丘脑、下丘脑、杏仁核、皮质和黑质。在隔区、丘脑、下丘脑、杏仁核和皮质中检测到的低密度[(3)H]5-CT结合位点可被10 μM的选择性5-HT(7)受体拮抗剂(R)-3-(2-(2-(4-甲基哌啶-1-基)乙基)吡咯烷-1-磺酰基)苯酚(SB-269970)取代。在5-HT(1A/1B)基因敲除小鼠的苍白球和黑质中检测到的对SB-269970不敏感的[(3)H]5-CT结合位点可被N-[3-(2-二甲基氨基)乙氧基-4-甲氧基苯基]-2'-甲基-4'-(5-甲基-1,2,4-恶二唑-3-基)-(1,1'-联苯)-4-甲酰胺盐酸盐(SB-216641)(1 μM)取代,表明这些结合位点具有5-HT(1D)特性。与低密度的[(3)H]5-CT结合位点相反,在5-HT(1A)和5-HT(1A/1B)基因敲除小鼠的整个脑中(嗅觉系统、隔区、丘脑、下丘脑、杏仁核、海马体CA3区、皮质被膜和中央灰质)发现了高至中等密度的[(3)H]8-OH-DPAT结合位点(10 nM)。这些[(3)H]8-OH-DPAT结合位点可被10 μM SB-269970、利培酮和甲硫哒嗪取代,但不能被吲哚洛尔、N-叔丁基-3-[4-(2-甲氧基苯基)哌嗪-1-基]-2-苯基丙酰胺(WAY-100135)或西酞普兰取代。我们得出结论,尽管[(3)H]5-CT在组织匀浆中对5-HT(7)受体具有高亲和力,但它并不是放射自显影测量5-HT(7)受体结合位点的良好示踪剂。此外,亲和力较低的配体[(3)H]8-OH-DPAT是5-HT(7)受体结合位点放射自显影研究中更好的示踪剂。